Dr. Hua Yu is Billy Wilder Endowed Professor, Co-Leader of Cancer Immunotherapeutics Program, City of Hope Comprehensive Cancer Center. Dr. Yu is a noted expert and pioneer on the role of STAT3 in cancer inflammation, which is critical for aging. She was the first to uncover and define the protein’s effect on inducing immunosuppression in cancer. Dr. Yu’s studies have laid the foundation for a new generation of molecular targeted cancer therapy approaches that disable both tumor cell growth and inhibit cancer-promoting inflammation. She has developed potentially paradigm-shifting novel siRNA, antibody and CRISPR delivery technology platforms to inhibit STAT3 and other challenging targets critical for cancer and aging (inflammation). Dr. Yu received her bachelor’s and doctoral degrees from Columbia University in New York City. She completed fellowships with the American Cancer Society and the National Institutes of Health. The fundamental discoveries from her laboratory have been well supported continuously by grants from the National Institutes of Health. Her recent studies have been published extensively in such prestigious biomedical /cancer research journals as Nature Medicine, Cancer Cell, Nature Biotechnology, Immunity and Cell Metabolism. She is also the corresponding author of multiple review articles on STAT3 in cancer / inflammation in Nature Reviews Cancer and Nature Reviews Immunology.
City of Hope, USA